Antibody Drug Conjugates Market Will Hit at A CAGR of 14.0% and To Garner US$ 11.01 Bn by 2028 | F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc

Overview:

Antibody drug conjugates (ADCs) are a new class of drugs that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of ADCs is fairly straightforward. When ADCs are administered intravenously and binds to a target molecule, causing cell death. Four ADCs are currently FDA-approved for the treatment of solid tumors.

Apply Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/181

Drivers:

Rise in research and development activities is expected to propel growth of the global antibody drug conjugates market over the forecast period. For instance, in November 2020, CytomX Therapeutics, Inc. announced the treatment of the first patient in Phase 2 expansion study of CX-2029, an anti-CD71 Pro-body drug conjugate. The study, in collaboration with AbbVie, is evaluating CX-2029 as monotherapy in four cohorts; such as esophageal cancer, squamous head and neck cancer (sqHNSCC), squamous non-small cell lung cancer (sqNSCLC), and diffuse large B-cell lymphoma (DLBCL).

Moreover, market players are adopting various strategies, such as collaborations, partnerships, and acquisitions, to strengthen their product portfolio, which in turn is expected to drive growth of the global antibody drug conjugates market. For instance, in December 2020, Boehringer Ingelheim acquired NBE-Therapeutics for a total of € 1.18 billion (US$ 1.43 billion) to enhance its cancer pipeline portfolio.

COVID-19 Impact:

The pandemic has severely affected many markets across the world. The pandemic has affected both the demand and the supply of healthcare products in three main ways; such as by creating disruptions in distribution channels, by directly affecting the production and demand, and due to its financial impact on firms and financial markets. This in turn is expected to hamper growth of the global antibody drug conjugates market. For instance, according to the article published in September 2020 in the journal of JCO Global Oncology, over 356 centers from 54 countries across six continents participated in the study, between April 21 and May 8, 2020. Around 716,979 new cancer patients are treated every year in these facilities. During the pandemic, most of them (88.2%) reported difficulties in providing cancer care. The pandemic has severely affected cancer care, with varying magnitudes across centers worldwide.

Regional Insights:

North America is expected to witness robust growth in the global antibody drug conjugates market due to the introduction of novel and approved products in the market. For instance, in December 2019, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer.

Key Players:

Key players active in the global antibody drug conjugates market are Oxford Biotherapeutics, Daiichi Sankyo Company Ltd., Seagen, Inc., Pfizer, Inc., Astellas Pharma, GlaxoSmithKline, Gilead Sciences, F. Hoffmann-La Roche Ltd., ADC Therapeutics, and Takeda Pharmaceutical Company Ltd., among others.

Direct Purchase This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/181

Reasons to Buy this Antibody Drug Conjugates Market Report

➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Antibody Drug Conjugates Market

➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Antibody Drug Conjugates Market

➡Leading company profiles reveal details of key Antibody Drug Conjugates Market players emerging five operations and financial performance

➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Antibody Drug Conjugates Market with five year historical forecasts

➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Antibody Drug Conjugates Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Antibody Drug Conjugates Industry Impact

Chapter 2 Global Antibody Drug Conjugates Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antibody Drug Conjugates (Volume and Value) by Type
2.3 Global Antibody Drug Conjugates (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Antibody Drug Conjugates Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Antibody Drug Conjugates Market Analysis
Chapter 6 East Asia Antibody Drug Conjugates Market Analysis
Chapter 7 Europe Antibody Drug Conjugates Market Analysis
Chapter 8 South Asia Antibody Drug Conjugates Market Analysis
Chapter 9 Southeast Asia Antibody Drug Conjugates Market Analysis
Chapter 10 Middle East Antibody Drug Conjugates Market Analysis
Chapter 11 Africa Antibody Drug Conjugates Market Analysis
Chapter 12 Oceania Antibody Drug Conjugates Market Analysis
Chapter 13 South America Antibody Drug Conjugates Market Analysis
Chapter 14 Company Profiles and Key Figures in Antibody Drug Conjugates Business
Chapter 15 Global Antibody Drug Conjugates Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology